NEW YORK, April 01, 2016 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Imprivata, Inc. securities (NYSE:IMPR) from July 30, 2015 through November 2, 2015, inclusive (the “Class Period”) of the important April 4, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Imprivata investors under the federal securities laws.
To join the Imprivata class action, go to the firm’s website at http://rosenlegal.com/cases-839.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants issued materially false and misleading statements to investors and/or failed to disclose information concerning demand for its IT security offerings and sales trends, which artificially inflated the price of Imprivata stock. In addition, the lawsuit alleges that certain Imprivata executives capitalized on the inflated stock value by selling millions of shares during the time period in question. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 4, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://rosenlegal.com/cases-839.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Grok AI Faces Global Scrutiny Over Safeguard Failures and Illegal Content on X
Bain Capital Moves to Acquire Majority Stake in Echo Marketing
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 



